Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated November 7, 2016, serves as a current report for Ultragenyx Pharmaceutical Inc. The filing announces the company's financial results for the three and nine months ended September 30, 2016. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K filing.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms the issuance of results for the periods ended September 30, 2016.
Guidance, Outlook, and Risks
The filing does not include specific guidance, outlook, management commentary, or risk factors within the text provided. It notes that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference, except as expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 7, 2016) for actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones and clinical trial updates mentioned in the press release.
- Confirm the company's cash runway and burn rate as detailed in the full financial report.
- Check for any forward-looking statements or guidance updates in the attached press release.